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Kidney disease and children – optimising care when prevention fails 
 
The theme for World Kidney Day in 2016 was “kidney disease and children: act early to prevent it”. 
Given the adverse impact of renal replacement therapy (RRT) – encompassing dialysis and 
transplantation – on quality of life and health care resources, there can be few who would disagree 
with this ambition. For some children, however, end-stage kidney disease (ESKD) cannot be avoided 
and its impact has to be managed and outcomes optimised. With increasing fiscal pressures on 
health services, the accompanying paper by Chesnaye and colleagues looking at macroeconomics 
and survival on RRT in Europe is very timely [1]. 
In children, as in adults, spending more on healthcare is associated with higher treatment rates [2, 
3], presumably because any benefits from resource spent on preventing ESKD are outweighed by a 
combination of reductions in competing events and improved availability of RRT. When it comes to 
survival on RRT, however, different patterns are seen in children and adults: higher expenditure on 
healthcare is associated with better survival on RRT for children [1] but poorer survival on RRT for 
adults [4]. While accepting the limitations of such high-level analyses, these findings do seem to 
suggest differences in the marginal gains from accepting individuals at the opposite extremes of age 
onto RRT programmes.  
Taking a macroeconomic focus in the models creates difficulties when benchmarking performance 
between countries, however. Some low-income countries may be falsely reassured when their 
mortality rate looks better after adjustment for how little they spend. High-income countries may be 
falsely reassured by their performance against the European average because that European 
average includes some Eastern European countries with very low performance. Furthermore, the 
comparison should ideally be between age-adjusted rates – France has an older age distribution (i.e. 
at lower risk) than the average (as demonstrated by the increase in hazard with adjustment for age 
in Figure 2 in [1]) and a lower RRT incidence rate compared with the UK (6.3 vs 9.8 per million of the 
population) [2]. We should also really be looking at outcomes for those with ESKD, rather than RRT 
which ignores outcomes in those who aren’t accepted onto treatment.  Finally, at least in countries 
with good survival rates, we need to become more patient-centred and take account of quality of 
life with validated tools [5] as well as psychosocial outcomes (Figure 1).  
The implications for clinical practice also need careful consideration. One possible modifiable 
explanation for these differences is variation in access to kidney transplantation. Although kidney 
transplant rates have been included in the model, because of queue theory [6] these will not 
necessarily reflect the known marked differences in the time children wait for a transplant. Waiting 
times are known to differ markedly between countries and have been shown to be determined by 
non-medical factors [7, 8]. For example, a child will wait 6 months for a transplant in France 
compared with 15 months in the UK, 26 months in the Netherlands and 30 months in Russia [7].  
This is relevant because kidney transplantation confers a survival advantage over remaining on 
dialysis: once children have survived the first few months of kidney transplantation their mortality 
risk is at least half of what it would have been had they stayed on dialysis [9]. 
Transplantation is clearly not the only explanation and many other factors need to be systematically 
explored. One framework for such an approach promulgated by the Cochrane Equity Methods 
Group is PROGRESS plus, which lists factors of social disadvantage that may impact upon an 
individual’s access to healthcare, such as place of residence, religion, occupation, gender, race, 
education, social capital, socio-economic position, social status, plus age and disability. [10] An 
equity-focused systematic review in adults on dialysis found socially determined factors including 
low education levels and geographic remoteness were associated with 54% higher risk of 
cardiovascular events and 21% higher mortality [11].   
Overall we feel it is reassuring that a greater proportion of gross domestic product (GDP) spent on 
healthcare is associated with survival gains for children. This represents a good return on investment 
of public monies. It would be interesting to know where the “sweet spot” is – that is, at what 
percentage of GDP spent on healthcare do the gains in child survival level off? Or is the relationship 
linear?  
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Figure 1. Survival of children aged less than 16 started on renal replacement therapy in the UK 
between 2000 and 2013, stratified by age at start of treatment: the importance on improving 
patient-centred outcomes (adapted with permission from [12]). 
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